MoonLake Immunotherapeutics (MLTX) Prices 8M Share Offering at $50/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls as traders digest escalation in US-Iran strikes
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
June 28, 2023 5:00 AM EDTMoonLake Immunotherapeutics Announces Pricing of $400 Million
Upsized Public Offering of Class A Ordinary Shares
ZUG, Switzerland, June 28, 2023 MoonLake Immunotherapeutics (Nasdaq: MLTX) (MoonLake), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced the pricing on June 27, 2023 of its upsized underwritten public offering of 8,000,000 Class A ordinary shares at a public offering price per share of $50.00. The gross... More
